Please assess the completion status of the following clinical trial:

Trial Title: Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* performance of a SARS-CoV-2 test within 1 day of enrollment, N.B., must be positive to proceed to treatment phase of the trial~Exclusion Criteria:~* All patients under 18~* Known allergy to N-Acetyl Cysteine~* Known allergy to famotidine or other H2-receptor antagonists~* Pregnant or Nursing Mothers~* Laboratory Evidence or History of Renal Impairment (eGFR \< 30 mL/min/1.73 m2)~* Taking H2-receptor antagonists, hydroxychloroquine or chloroquine.~* Patient has been admitted to the hospital prior to study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose N-Acetyl Cysteine Alone (Type: EXPERIMENTAL): N-Acetyl Cysteine 600 mg three times daily
- Medium Dose N-Acetyl Cysteine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,200 mg three times daily
- Low Dose N-Acetyl Cysteine and Low Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 600 mg three times daily Famotidine 20 mg three times daily
- High Dose N-Acetyl Cysteine Alone (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,800 mg three times daily
- Medium Dose N-Acetyl Cysteine and Low Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,200 mg three times daily Famotidine 20 mg three times daily
- Low Dose N-Acetyl Cysteine and Medium Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 600 mg three times daily Famotidine 40 mg three times daily
- High Dose N-Acetyl Cysteine and Low Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,800 mg three times daily Famotidine 20 mg three times daily
- Medium Dose N-Acetyl Cysteine and Medium Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,200 mg three times daily Famotidine 40 mg three times daily
- Low Dose N-Acetyl Cysteine and High Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 600 mg three times daily Famotidine 80 mg three times daily
- High Dose N-Acetyl Cysteine and Medium Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,800 mg three times daily Famotidine 40 mg three times daily
- Medium Dose N-Acetyl Cysteine and High Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,200 mg three times daily Famotidine 80 mg three times daily
- High Dose N-Acetyl Cysteine and High Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,800 mg three times daily Famotidine 80 mg three times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).